摘要
目的以环孢菌素(CSA)为模型药物,在NONMEM程序构建的群体药动学模型的基础上,通过EXCEL实现个体化给药。方法以群体药动学模型为基础,采用1～2个实测的血药浓度点在EXCEL中运用最小二乘法估算每位病人个体间差异值。根据给药剂量、病人个体信息、个体间差异值和残留随机效应值进一步计算得出预测血药浓度值和预测血药浓度变异范围。结果由实测的ρ0(谷浓度)为基础估算个体间差异值,进而得到的预测血药浓度与观测值拟合较好,优于采用ρ2(给药后2h浓度)、或ρ0加ρ2时所得的结果。结论在群体药动学系统分析的基础上,运用EXCEL通过1个血药浓度实测值可以实现个体化给药。
Abstract
OBJECTIVE To construct a population pharmacokinetic model for cyclosporine, which was constructed by NONMEM, and to adjust administration individually.METHODS Based on the population pharmacokinetic model, least square method was employed to estimate patient inter-individual variability, with one or two blood samplings. Then it was feasible to predict the concentration and its range according to dose, personal information, inter-individual variability and intra-individual variability.RESULTS ρ0 (predosing concentration) was used to estimate the inter-individual variability and then predicted blood concentrations. The observed concentrations were matched well by ρ0 prediction and were better than those calculated by ρ2 (concentration at 2 h after dosing) and the union of ρ0 and ρ2. CONCLUSION It is feasible to perform individual administration with only one concentration using EXCEL, based on the results of population pharmacokinetics.
关键词
环孢菌素 /
NONMEM /
群体药动学 /
个体化给药
{{custom_keyword}} /
Key words
cyclosporine /
NONMEM /
population pharmacokinetics
{{custom_keyword}} /
吴克华;卢炜;李静;崔一民;崔福德;张扬.
环孢菌素群体药动学的研究及应用[J]. 中国药学杂志, 2006, 41(23): 1818-1821
WU Ke-hu;LU Wei;LI Jing;CUI Yi-min;CUI Fu-de;ZHNG Yng.
Population Pharmacokinetic Study of Cyclosporine and Its Application [J]. Chinese Pharmaceutical Journal, 2006, 41(23): 1818-1821
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] HESSELINK D A，SMAK GREGOOR P J H，WEIMAR W. The use of cyclosporine in renal transplantation transplantation[J] . Proceedings，2004，36 (Suppl 2S)： 99S-106S.
[2] TSUNODA S M，AWEEKA F T. The use of therapeutic drug monitoring to optimise immunosuppressive therapy[J] .Clin Pharmacokinet，1996，30： 107-140.
[3] BEAL S L，SHEINER L B. NONMEM Users Guide[M] . NONMEM Project Group，University of California，San Francisco，CA 94143，1999，PartⅤ：101-128.
[4] PARKE J，CHARLES B G. Factors affecting oral cyclosporine disposition after heart transplantation： bootstrap validation of a population pharmaceutic model[J] .Eur J Clin Pharmacol，2000，56： 481-487.
[5] REN B，LI S X，WANG C X，et al. Estimation of relative clearance of cyclosprine A in patients after renal transplantation using nonlinear mixed effect model[J] .Chin Pharm J，2003，38(9)： 692-694.
[6] PARKE J，CHARLES B G. NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation[J] .Ther Drug Monit，1998，20(3)： 284-293.
[7] JACOBSON P A，NG J，GREEN K G，et al. Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation[J] .Biol Blood Marrow Transplant，2003，9(5)： 304-311.
[8] RUI J Z，CAO X F，LI J H，et al. Population pharmacokinetic modeling of orally administered cyclosporine A from routine drug monitoring data after renal transplantation in Chinese[J] .Chin J Clin Pharmacol(中国临床药理学杂志)，2002，12(6)： 431-437.
[9] RUI J Z，ZHUO H T，JIANG G H，et al. Evaluation of population pharmacokinetics of cyclosporine in renal transplantation patients with NONMEM[J] .Acta Pharmaceutica Sinica，1995，30(4)： 241-247.
[10] KEHUA W U，YIMIN C，WEI L U，et al. Population pharmacokinetics of cyclosporine in clinical renal transplant patients[J] .Drug Metab Dispos，2005，33(9)： 1268-1275.
[11] TROMPETER R，FITZPATRICK M，HUTCHINSON C，et al. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption[J] .Pediatr Transplant，2003，7： 282-288.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
